Login – Field Link

An AI-powered self-explorer platform for HCPs

Explore pharmaceutical industry products

If you are a healthcare professional, please register for access

This website is for healthcare professionals (HCPs) only

Features and Benefits

Explore in your own time

A single source to access industry materials

Review the evidence and form your own conclusion

Introducing the AI assistant LEX

The LEX self-detailer platform is an integrated support tool within the OZURDEX® digital sales aid, designed to provide concise, evidence-based information to healthcare professionals. This smart assistant is designed to answer any questions you may have about OZURDEX®, whether it’s product information, clinical data, or usage guidance. Simply type your question into the Ask LEX tab at any point during your digital journey, and get instant, reliable answers to support your conversation.

How to navigate the LEX AI platform

As you navigate the OZURDEX® digital sales aid, the Ask LEX tab will pop up to assist you. You can enter any question related to OZURDEX®, including product information, clinical data, and administration guidance. The LEX pop-up tab can be closed at any time, allowing you to continue exploring the sales aid without interruption.

TIPS

Be clinically precise - use accurate medical terminology and clearly define the expected output to ensure relevant responses
Refine your questions - enhance the AI’s response by asking questions tailored to the OZURDEX® Product Information, PBS guidance and key clinical papers. Consider topics such as indication, dosing, administration, precautions, efficacy, safety in diabetic macular oedema (DMO) and retinal vein occlusion (RVO)
Refine your prompts - to enhance the depth and relevance of LEX’s responses, consider asking follow-up questions that are similar in intent to your original query but slightly reworded. This technique encourages LEX to expand on its initial answer and provide additional context or clarification

EXAMPLE QUESTIONS

Who can ophthalmologists prescribe OZURDEX® to?
Who is eligible for OZURDEX® under the PBS in Australia?
Can a patient with a contraindication to VEGF inhibitors access OZURDEX® for DMO through the PBS?
Has any clinical research been conducted on the simultaneous administration of OZURDEX® to both eyes?
What should be done before the OZURDEX® intravitreal injection to prepare the patient’s medical history and the injection site?
What are the contraindications for OZURDEX®?
What are the potential complications of intravitreal OZURDEX® injections?
What are the functional outcomes for OZURDEX® in DME clinical trials?
Does the risk of cataract increase with repeated OZURDEX® injections in RVO patients?
What outcomes have been observed in patients who remained on anti-VEGF therapy versus those who switched to dexamethasone?

1 of 3

Allowed to be displayed on HCP portal

Change Log:
Created: {{UserEmail}} {{Date Creation}}
Last Changed: {{UserEmail}} {{Date of Change}}
Published: {{Date Published}}
Version: {{X.X}}

Brand

Therapy area

Indication

Headline

Description

PBS Information

Refer to Product Information Text Add link text

Features and Benefits

Upload successful